Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.

Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield MT, Han MK, Make B, Marchetti N, Martinez FJ, Niewoehner DE, Scanlon PD, Sciurba FC, Scharf SM, Sin DD, Voelker H, Washko GR, Woodruff PG, Lazarus SC; COPD Clinical Research Network; Canadian Institutes of Health Research.

N Engl J Med. 2014 Jun 5;370(23):2201-10. doi: 10.1056/NEJMoa1403086. Epub 2014 May 18.

2.

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.

Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, Sardina M, Gao Y, Wang BS, Zhong NS; PANTHEON study group.

Lancet Respir Med. 2014 Mar;2(3):187-94. doi: 10.1016/S2213-2600(13)70286-8. Epub 2014 Jan 30. Erratum in: Lancet Respir Med. 2014 Apr;2(4):e4.

PMID:
24621680
3.

Long-acting beta2-agonists for chronic obstructive pulmonary disease.

Kew KM, Mavergames C, Walters JA.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD010177. doi: 10.1002/14651858.CD010177.pub2. Review.

PMID:
24127118
4.

Aclidinium bromide for stable chronic obstructive pulmonary disease.

Ni H, Soe Z, Moe S.

Cochrane Database Syst Rev. 2014 Sep 19;(9):CD010509. doi: 10.1002/14651858.CD010509.pub2. Review.

PMID:
25234126
5.

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE; SUMMIT Investigators.

Lancet. 2016 Apr 30;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1. Epub 2016 Apr 28.

PMID:
27203508
6.

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.

Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R.

Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7.

7.

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.

Wang C, Sun T, Huang Y, Humphries M, Bai L, Li L, Wang Q, Kho P, Firth R, D'Andrea P.

Int J Chron Obstruct Pulmon Dis. 2015 Jan 5;10:57-68. doi: 10.2147/COPD.S72650. eCollection 2015. Erratum in: Int J Chron Obstruct Pulmon Dis. 2015;10:1513.

8.

Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.

Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG.

JAMA. 2013 Jun 12;309(22):2353-61. doi: 10.1001/jama.2013.5732.

PMID:
23757083
9.

Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial.

John ME, Cockcroft JR, McKeever TM, Coward WR, Shale DJ, Johnson SR, Thornton JG, Harrison TW, Knox AJ, Bolton CE.

Int J Chron Obstruct Pulmon Dis. 2015 Jan 29;10:211-21. doi: 10.2147/COPD.S76061. eCollection 2015.

10.

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.

Cheyne L, Irvin-Sellers MJ, White J.

Cochrane Database Syst Rev. 2015 Sep 22;(9):CD009552. doi: 10.1002/14651858.CD009552.pub3. Review.

PMID:
26391969
11.

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.

Cheyne L, Irvin-Sellers MJ, White J.

Cochrane Database Syst Rev. 2013 Sep 16;(9):CD009552. doi: 10.1002/14651858.CD009552.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(9):CD009552.

PMID:
24043433
12.

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF.

Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13.

PMID:
25684586
13.
14.

Tiotropium versus placebo for chronic obstructive pulmonary disease.

Karner C, Chong J, Poole P.

Cochrane Database Syst Rev. 2014 Jul 21;(7):CD009285. doi: 10.1002/14651858.CD009285.pub3. Review.

PMID:
25046211
15.

A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.

Anzueto A, Niewoehner DE, Leimer I, Rühmkorf F, Celli BR, Decramer M, Tashkin DP.

Respir Med. 2013 Dec;107(12):1912-22. doi: 10.1016/j.rmed.2013.07.020. Epub 2013 Aug 20.

16.

Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.

Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.

Respir Med. 2013 Apr;107(4):542-9. doi: 10.1016/j.rmed.2012.12.020. Epub 2013 Jan 20.

17.

Tiotropium versus placebo for chronic obstructive pulmonary disease.

Karner C, Chong J, Poole P.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD009285. doi: 10.1002/14651858.CD009285.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(7):CD009285.

PMID:
22786525
18.

Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.

Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ.

Respir Med. 2012 Feb;106(2):257-68. doi: 10.1016/j.rmed.2011.07.020. Epub 2011 Oct 26.

19.

Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).

Herath SC, Poole P.

Cochrane Database Syst Rev. 2013 Nov 28;(11):CD009764. doi: 10.1002/14651858.CD009764.pub2. Review.

PMID:
24288145
20.

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.

Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12. Erratum in: Lancet Respir Med. 2013 May;1(3):186.

PMID:
24429127

Supplemental Content

Support Center